Singapore: Takeda Pharmaceutical Company and Pfizer Japan have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth K K and currently distributes under an exclusive distribution agreement with Pfizer, and that Pfizer, the manufacturer of the products, will begin selling them thereafter. In addition, Takeda will continue to distribute the pneumococcus vaccine Prevenar for infants and young children and hemophilia B drug BeneFIX after January 2013.

Aside from this exclusive distribution agreement, the two companies agreed in February 2011 to extend the term of co-promotion agreement of the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept), the marketing of which Takeda will continue.